XFOR (X4 Pharmaceuticals) Current Deferred Revenue: $0.91 Mil (As of Mar. 2026)


XFOR X4 Pharmaceuticals Inc XFOR
24 GF Score
Price $4.12
! 7 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals Current Deferred Revenue?

X4 Pharmaceuticals XFOR +1.10% 24 Current Deferred Revenue is $0.91 Mil as of Mar. 2026. GuruFocus rates XFOR with a GF Score™ of 24/100. The stock has 7 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

X4 Pharmaceuticals's current deferred revenue for the quarter that ended in Mar. 2026 was $0.91 Mil.

X4 Pharmaceuticals Current Deferred Revenue Related Terms

X4 Pharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for X4 Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals Current Deferred Revenue Chart

X4 Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.46

X4 Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.75 0.59 0.46 0.91
XFOR
24GF Score
X4 Pharmaceuticals Inc XFOR
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.91 Mil mean?
X4 Pharmaceuticals (XFOR) has a Current Deferred Revenue of $0.91 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on X4 Pharmaceuticals and its competitors.
Is X4 Pharmaceuticals' Current Deferred Revenue too high?
X4 Pharmaceuticals' current Current Deferred Revenue is $0.91 Mil. Overall, X4 Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Current Deferred Revenue compare to CMPX and LRMR?
X4 Pharmaceuticals' Current Deferred Revenue of $0.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current Current Deferred Revenue is $0.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current Current Deferred Revenue of $0.91 Mil. The current Current Deferred Revenue is $0.91 Mil. X4 Pharmaceuticals' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Current Deferred Revenue is $0.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
24GF Score

Get the complete analysis for XFOR

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12
Price